Makerere University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kampala Uganda (1922)

Organization Overview

First Clinical Trial
2000
NCT00344669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CHDC-Makerere University | College of Health Sciences, Makerere University, Uganda | Department of Anesthesia and Critical Care, Makerere University, College of Health Sciences, Kampala,Uganda | Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University | Department of Medicine, Makerere University, Kampala, Uganda | Department of Obstetrics and Gynecology, Makerere University | Department of paediatrics and Child Health, Makerere University | Department of Paediatrics and Child Health , Makerere University | Department of Paediatrics and Child Health, Makerere University | Department of Paediatrics and Child Health Makerere University, Kampala, Uganda | Department of Pediatrics, Makerere University, Kampala, Uganda | Dept of Paediatrics and Child Health, Makerere University, Uganda | HCRI-Ug, Makerere University | Infectious Diseases Institute | Infectious Diseases Institute at Makerere University | Infectious Diseases Institute, Makerere University | Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda | Makarere Univeritys ; Infectious Disease Research Collaboration | MakCHS | Makerere University | Makerere University Collage of Health Sciences, Department of Obstetrics and Gynecology | Maker ere University College of Health, Kampala, Uganda | Makerere University, college of Health Sciences | Makerere University College of Health Sciences | Makerere University College of Health Sciences Department of Anaesthesia | Makerere University, College of Health Sciences, Department of Anaesthesia and Critical care | makerere university college of health sciences department of anesthesia | Makerere University, College of Health Sciences, Department of Anesthesia and Critical Care | Makerere University, College of Health Sciences, Department of Child Health and Pediatrics | Makerere University College of Health Sciences, Kampala, Uganda | Makerere university dept of anesthesia | Makerere University; IDRC | Makerere University; Infectious Disease Research Collaboration | Makerere University; Infectious Diseases Research Collaboration | Makerere University Institute of Public Health | Makerere University Kampala | Makerere University, Makerere, Uganda | Makerere University Medical School, Makerere University, Kampala, Uganda | Makerere University Walter Reed Project | Makerere Univ. Institute of Public Health, Dept. of Epidemiology and Biostatistics | School of Public Health, Makerere University

Active Ingredients

Drugs in Phase 4 Trials (30)

artemether (1 trial)

ceftriaxone (rocephin) (3 trials)

chlorhexidine (hibitane) (1 trial)

coartem (7 trials)

desogestrel (Mercilon) (1 trial)

dihydroartemisinin (4 trials)

efavirenz (sustiva) (6 trials)

emtricitabine (emtriva) (2 trials)

ethambutol (myambutol) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fluconazole (diflucan) (2 trials)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

ketamine (ketalar) (3 trials)

lamivudine (epivir) (6 trials)

levobupivacaine (chirocaine) (3 trials)

lopinavir (Kaletra) (4 trials)

lumefantrine (Coartem) (9 trials)

medroxyprogesterone (provera) (1 trial)

metronidazole (flagyl) (2 trials)

morphine (3 trials)

nevirapine (viramune) (6 trials)

norgestrel (Ovral) (2 trials)

piperaquine (4 trials)

pyrazinamide (Aldinamide) (1 trial)

pyridoxine (1 trial)

quinine (qualaquin) (3 trials)

rifampin (4 trials)

ritonavir (Norvir) (6 trials)

stavudine (zerit) (2 trials)

tenofovir (viread) (3 trials)

Drugs in Phase 3 Trials (44)

abacavir (ziagen) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

amodiaquine (camoquin) (3 trials)

amphotericin b (fungizone) (1 trial)

ampicillin (1 trial)

artesunate (4 trials)

atorvastatin (lipitor) (2 trials)

bacille calmette-guerin (1 trial)

carvedilol (coreg) (1 trial)

clindamycin (cleocin) (1 trial)

darunavir (prezista) (3 trials)

dihydroqinghaosu (8 trials)

dolutegravir (tivicay) (3 trials)

fexinidazole (1 trial)

gentamicin (garamycin) (1 trial)

hydroxyurea (hydrea) (3 trials)

inactivated influenza vaccine (2 trials)

isoniazid (nydrazid) (2 trials)

ivermectin (stromectol) (1 trial)

mannitol (1 trial)

midazolam (versed) (1 trial)

miltefosine (impavido) (1 trial)

misoprostol (cytotec) (4 trials)

multivitamins (1 trial)

oxygen (1 trial)

pancrelipase (creon) (1 trial)

paromomycin (humatin) (1 trial)

piperaquinoline (8 trials)

procaine benzylpenicillin (novocaine) (2 trials)

pyrimethamine (daraprim) (6 trials)

rifapentine (priftin) (1 trial)

rosuvastatin (crestor) (1 trial)

sertraline (zoloft) (1 trial)

sodium stibogluconate (1 trial)

sulfadoxine (6 trials)

sulfamethoxazole (gantanol) (3 trials)

tranexamic acid (cyklokapron) (1 trial)

trimethoprim (3 trials)

Tuberculin, Purified Protein Derivative (Tubersol) (1 trial)

ursodeoxycholic acid (1 trial)

valganciclovir (valcyte) (1 trial)

zidovudine (retrovir) (3 trials)

zinc (1 trial)

zinc dichloride (1 trial)

Drugs in Phase 2 Trials (16)

aluminum hydroxide (Gaviscon) (1 trial)

autologous adipose-derived mesenchymal stem cells (1 trial)

doxycycline (vibramycin) (1 trial)

engerix-b (1 trial)

etonogestrel (1 trial)

gluco-pyranosylphospho-lipid (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

levonorgestrel (1 trial)

minocycline (minocin) (1 trial)

nitric oxide (inomax) (1 trial)

praziquantel (biltricide) (2 trials)

remdesivir (1 trial)

rilpivirine (edurant) (2 trials)

sm-tsp-2 (1 trial)

triamcinolone (kenalog) (1 trial)

urea (2 trials)

Drugs in Phase 1 Trials (6)

ebola vaccine (1 trial)

lorazepam (ativan) (1 trial)

marburg vaccine (1 trial)

vcp1521 (1 trial)

vrchivadv014-00-vp (1 trial)

vrc-hivdna009-00-vp (1 trial)

Drugs in Other Trials (14)

acetaminophen (tylenol) (1 trial)

acetic acid (vosol) (1 trial)

albendazole (Albenza) (2 trials)

allogeneic blood cells (1 trial)

chloroquine (1 trial)

COVID-19 convalescent plasma (1 trial)

fentanyl (Innovar) (1 trial)

fluoxetine (prozac) (1 trial)

glucose monohydrate (1 trial)

lidocaine (xylocaine) (1 trial)

oxytocin (syntocinon) (1 trial)

ringer's lactate (1 trial)

sodium chloride (2 trials)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Acute Pain (Phase 4)

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Asphyxia (Phase 3)

Asphyxia Neonatorum (Phase 3)

Blister (Phase 3)

Bone Demineralization, Pathologic (Phase 4)

Catatonia (Phase 1)

Child Nutrition Disorders (Phase 3)

Cognitive Dysfunction (Phase 2)

Critical Illness (Phase 3)

Cryptococcosis (Phase 4)

Cytomegalovirus Infections (Phase 3)

Diarrhea (Phase 3)

Fetal Distress (Phase 3)

Hemorrhage (Phase 3)

Hemorrhagic Fever, Ebola (Phase 1)

Hepatitis (Phase 4)

Hepatitis B (Phase 4)

HIV Infections (Phase 4)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 4)

Keloid (Phase 2)

Leiomyoma (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Visceral (Phase 3)

Malaria (Phase 4)

Malaria, Cerebral (Phase 3)

Malnutrition (Phase 3)

Marburg Virus Disease (Phase 1)

Maternal Death (Phase 3)

Meningitis (Phase 4)

Meningitis, Cryptococcal (Phase 4)

Meningitis, Fungal (Phase 3)

Nodding Syndrome (Phase 2)

Pain, Postoperative (Phase 4)

Pneumonia (Phase 3)

Postpartum Hemorrhage (Phase 3)

Respiratory Tract Infections (Phase 3)

Schistosomiasis (Phase 2)

Schistosomiasis mansoni (Phase 2)

Seizures (Phase 2)

Sepsis (Phase 4)

Stroke (Phase 3)

Syndrome (Phase 1)

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Tuberculosis (Phase 4)

Uterine Cervical Neoplasms (Phase 3)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 122
  • # of Trial APIs: 110